Compare Enveric Biosciences Inc (ENVB) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Manhattan Associates Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Manhattan Associates Inc trades at $206.18 (market cap $11.79B). The key difference: Manhattan Associates Inc is far larger — about 1733.8× Enveric Biosciences Inc's market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Manhattan Associates Inc for 12 Days on average.
| ENVB | MANH | |
|---|---|---|
Market Cap | $6.80M | $11.79B |
Volume | 64,867 | 393,599 |
Sector | Health | Technology |
52-Week High | $10.80 | $223.76 |
52-Week Low | $1.27 | $120.88 |
Typical Hold Time | 14 Days | 12 Days |
Enterprise Value | -$1.49M | $11.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
MANH trades at $202.11, down 0.36% on the day, with a bearish technical signal and key support at $201. The company shows strong profitability with a net income margin of 18.67% and has beaten earnings estimates for the last three quarters. Recent news includes a law firm investigation into fiduciary duties and a product launch of Editions for its supply chain solutions.
The outlook is mixed: strong fundamentals and analyst buy ratings support upside to the $210.50 consensus target, but technical weakness and the ongoing legal investigation pose near-term risks. Earnings growth remains the key catalyst for further price appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
